Lakefront, in collaboration with Gilead, received Orphan Drug Designation from the FDA for gamgertamig, with trials active globally.

The entities involved

• company →

  legal entity representing an association of people, whether natural, legal or a mixture of both, with a specific objective

  • Board approved a quarterly cash dividend increase on August 1, 2026.Mon 15:06
  • A company incorporated in the Cayman Islands is publicly traded on Nasdaq.Mon 14:41
• Gilead Sciences →

  American company

  • Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.Sun 22:40
  • A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.Sat 01:51
• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Related events

• A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Jun 7
• FDA issued a partial clinical hold on trials involving Biohaven Ltd. on September 11, 2026.Sep 12
• EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.Jun 8
• TELIX Pharmaceuticals is conducting Phase 3 trials and seeking alignment on the New Drug Application pathway with the FDA.Sep 2
• Nkarta is seeking protocol amendments for its clinical trials under the FDA.Sun 19:56